Necrotizing enterocolitis (NEC), a devastating gastrointestinal disease primarily affecting preterm infants, continues to challenge neonatal care with its high rates of morbidity and mortality. Characterized by intestinal necrosis, severe inflammation, and hemorrhage, NEC not only undermines the gut’s integrity but also disastrously disrupts its repair mechanisms. Despite considerable advancements in neonatal intensive care, early diagnostic tools and effective targeted therapies remain elusive, leaving clinicians reliant on symptomatic management rather than precision medicine. However, a fascinating new frontier has emerged, spotlighting non-coding RNAs (ncRNAs) as pivotal players in the pathogenesis and potential treatment of NEC.
Non-coding RNAs, encompassing microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and transfer RNA-derived fragments (tRFs), are increasingly recognized for their roles in regulating diverse biological pathways. Unlike the traditional focus on protein-coding genes, ncRNAs orchestrate gene expression at transcriptional and post-transcriptional levels, influencing cell fate decisions, immune responses, and tissue remodeling. Recent research indicates that these molecules could offer unprecedented insights into NEC’s underlying molecular cascades, given their involvement in key inflammatory, apoptotic, angiogenic, and immune pathways.
The inflammatory milieu in NEC is notably complex, with excessive immune cell infiltration driving tissue destruction. MicroRNAs, for example, have been identified as critical regulators of inflammatory cytokines and signaling networks within NEC-affected intestines. Specific miRNAs may modulate toll-like receptor pathways and downstream effectors such as NF-κB, shaping the intensity and duration of inflammatory responses. By altering the expression of these miRNAs, it might be possible to dampen harmful inflammation while preserving essential host defenses, thus providing a new therapeutic axis to mitigate intestinal injury.
Long non-coding RNAs, a less studied class, exhibit versatile interaction capacities with DNA, RNA, and proteins, contributing to chromatin remodeling and transcriptional regulation. In NEC, lncRNAs appear to influence angiogenic responses necessary for intestinal repair by modulating vascular endothelial growth factors (VEGFs) and their receptors. Impaired angiogenesis exacerbates tissue ischemia, contributing to necrotic lesions; thus, lncRNA-mediated control of vascular processes may be essential to restoring gut integrity.
Adding another layer of complexity are the recently discovered tRNA-derived fragments, small ncRNAs generated through specific cleavage of tRNAs. These fragments have been implicated in modulating cellular stress responses and apoptosis, processes intimately linked with the pathophysiology of NEC. By regulating stress granule formation and mitochondrial function, tRFs may influence how preterm gut epithelial cells respond to hypoxic and inflammatory insults.
A particularly exciting avenue in NEC research involves the profiling of ncRNA signatures within affected tissues and systemic circulation. Distinct patterns of miRNAs, lncRNAs, and tRFs have been correlated with histopathological severity, suggesting their utility as biomarkers that can predict disease onset or progression. Plasma-derived exosomal ncRNAs, which are stable and readily accessible, offer a non-invasive window into intestinal health. Their detection could revolutionize early diagnosis, allowing clinicians to intervene before irreversible damage ensues.
Moreover, human milk has emerged as a natural reservoir of protective exosomal microRNAs. These miRNAs, delivered to the neonate through breastfeeding, may confer resilience against NEC by modulating host immune responses and enhancing epithelial barrier function. Understanding the specific miRNA profiles present in human milk could pave the way for therapeutic supplementation strategies, especially in infants unable to receive maternal milk.
Intriguingly, the interplay between ncRNAs and the gut microbiome is gaining recognition as a critical determinant of NEC susceptibility. Microbial metabolites and ncRNA expression patterns appear to influence one another bidirectionally, shaping immune tolerance and inflammatory responses in the immature intestine. This crosstalk opens the possibility of manipulating microbiome-ncRNA interactions to create a protective environment against NEC development.
Despite these promising insights, significant challenges remain. The heterogeneity of NEC pathophysiology complicates the identification of consistent ncRNA biomarkers applicable across diverse patient populations. Additionally, functional characterization of numerous lncRNAs and tRFs in intestinal development and injury responses is still in its infancy. These gaps necessitate larger-scale studies employing high-throughput sequencing technologies capable of capturing the full spectrum of ncRNA expression and their intricate regulatory networks.
Advances in single-cell sequencing and spatial transcriptomics offer powerful tools to delineate the cellular origins and targets of ncRNAs within the NEC-affected intestine. Mapping these molecules in situ will enhance understanding of their precise roles across different cell types, including enterocytes, immune cells, and endothelial populations, giving rise to more targeted and effective interventions.
The integration of multi-omics approaches combining ncRNA profiling with epigenomics, proteomics, and metabolomics will provide a holistic view of NEC pathogenesis, integrating molecular signals into coherent biological pathways. Such integrative analyses have the potential to identify master regulatory nodes amenable to therapeutic modulation, driving the field toward biomarker-guided precision medicine.
Current therapeutic strategies targeting ncRNAs are still experimental but hold immense promise. Synthetic miRNA mimics or inhibitors (antagomirs) could be designed to restore balances in deleterious signaling pathways, while delivery systems such as engineered exosomes could provide targeted transport to the inflamed gut mucosa, minimizing off-target effects. The safety and efficacy of such approaches in the fragile preterm infant population remain critical challenges to overcome.
In conclusion, non-coding RNAs represent an exciting and rapidly evolving domain within NEC research. Their multifaceted roles in orchestrating inflammation, cell death, repair, and immune modulation position them as both biomarkers for early detection and targets for innovative therapies. Ongoing research promises to transform NEC from a devastating neonatal condition into a disease that can be predicted, prevented, and precisely treated, improving outcomes for the most vulnerable infants.
As scientific understanding continues to advance, collaborations across neonatology, molecular biology, microbiology, and bioinformatics will be paramount. The translation of ncRNA discoveries into clinical practice requires rigorous validation in large, multi-center cohorts and carefully designed trials that address the unique challenges of preterm infants. Achieving this goal could redefine neonatal care, ushering in an era where molecular diagnostics and targeted treatments drastically reduce NEC’s toll on infants and families worldwide.
The future of NEC management lies in harnessing the power of the smallest molecular actors: non-coding RNAs. By illuminating their regulatory codes and leveraging their therapeutic potential, we stand at the precipice of a new paradigm—one where early biomarkers and novel interventions can save lives and prevent lifelong complications caused by this devastating disease.
Subject of Research:
The role of non-coding RNAs as biomarkers and therapeutic targets in the pathogenesis and management of necrotizing enterocolitis in preterm infants.
Article Title:
Emerging role of non-coding RNAs as biomarkers and therapeutic targets in preterm infants with necrotizing enterocolitis.
Article References:
Garg, P.M., Malhotra, A. Emerging role of non-coding RNAs as biomarkers and therapeutic targets in preterm infants with necrotizing enterocolitis. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04992-8
Image Credits: AI Generated
